Allspring Global Investments Holdings LLC Has $218.68 Million Position in BXP, Inc. $BXP

Allspring Global Investments Holdings LLC reduced its stake in shares of BXP, Inc. (NYSE:BXP) by 30.3% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,865,301 shares of the real estate investment trust’s stock after selling 1,243,392 shares during the period. Allspring Global Investments Holdings LLC owned 1.81% of BXP worth $218,680,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of BXP by 4.3% during the 2nd quarter. Vanguard Group Inc. now owns 24,470,390 shares of the real estate investment trust’s stock worth $1,651,017,000 after acquiring an additional 1,016,579 shares in the last quarter. State Street Corp raised its stake in shares of BXP by 1.7% in the second quarter. State Street Corp now owns 11,433,768 shares of the real estate investment trust’s stock valued at $782,337,000 after purchasing an additional 186,269 shares in the last quarter. Norges Bank bought a new position in BXP during the second quarter worth about $686,886,000. Geode Capital Management LLC grew its position in BXP by 1.7% in the second quarter. Geode Capital Management LLC now owns 4,153,844 shares of the real estate investment trust’s stock valued at $279,186,000 after acquiring an additional 68,481 shares during the period. Finally, Boston Partners increased its position in shares of BXP by 15.5% during the 2nd quarter. Boston Partners now owns 3,009,193 shares of the real estate investment trust’s stock worth $203,020,000 after purchasing an additional 403,090 shares in the last quarter. 98.72% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on BXP shares. Citigroup boosted their price objective on BXP from $70.00 to $75.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 10th. Cantor Fitzgerald assumed coverage on shares of BXP in a research report on Wednesday, October 1st. They set an “overweight” rating and a $90.00 price target on the stock. The Goldman Sachs Group set a $77.00 target price on BXP and gave the stock a “neutral” rating in a research note on Friday, October 17th. UBS Group boosted their price objective on shares of BXP from $68.00 to $74.00 and gave the company a “neutral” rating in a research report on Tuesday, September 9th. Finally, Royal Bank Of Canada raised shares of BXP to an “outperform” rating in a research note on Thursday, December 4th. Ten equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $79.10.

Insider Buying and Selling at BXP

In other BXP news, CFO Michael E. Labelle sold 13,422 shares of the business’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $72.34, for a total value of $970,947.48. Following the completion of the sale, the chief financial officer owned 9,223 shares of the company’s stock, valued at $667,191.82. The trade was a 59.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Raymond A. Ritchey sold 36,314 shares of the stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $72.18, for a total transaction of $2,621,144.52. The SEC filing for this sale provides additional information. Insiders have sold 70,710 shares of company stock worth $5,107,771 over the last quarter. Company insiders own 1.35% of the company’s stock.

BXP Stock Up 0.3%

Shares of BXP opened at $69.25 on Wednesday. The firm has a market cap of $10.97 billion, a P/E ratio of -54.53, a price-to-earnings-growth ratio of 6.45 and a beta of 0.99. The company has a debt-to-equity ratio of 2.26, a quick ratio of 4.50 and a current ratio of 4.50. BXP, Inc. has a 52 week low of $54.22 and a 52 week high of $79.33. The firm’s 50-day simple moving average is $70.76 and its 200 day simple moving average is $70.81.

BXP (NYSE:BXP) last issued its quarterly earnings data on Tuesday, October 28th. The real estate investment trust reported $1.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.02. The company had revenue of $871.51 million during the quarter, compared to analysts’ expectations of $860.88 million. BXP had a positive return on equity of 1.35% and a negative net margin of 5.82%.The business’s revenue was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.81 earnings per share. BXP has set its FY 2025 guidance at 6.890-6.920 EPS. On average, analysts forecast that BXP, Inc. will post 6.91 earnings per share for the current year.

BXP Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 29th. Investors of record on Wednesday, December 31st will be given a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a yield of 4.0%. The ex-dividend date of this dividend is Wednesday, December 31st. BXP’s dividend payout ratio (DPR) is currently -220.47%.

About BXP

Boston Properties, Inc (NYSE: BXP) is a publicly traded real estate investment trust (REIT) specializing in the ownership, management, and development of Class A office properties across major U.S. markets. Headquartered in Boston, Massachusetts, the company’s portfolio comprises high-quality office buildings, mixed-use developments and select retail assets designed to serve leading corporations in key metropolitan areas.

Established in 1970 by Mortimer B. Zuckerman, Boston Properties has grown through disciplined acquisitions and strategic ground-up developments.